Key result
Routine measurement of natriuretic peptides (BNP and NT-proBNP) for risk assessment in the general population or patients with hypertension and coronary disease is not currently indicated.
Why the study?
Does routine measurement of natriuretic peptides improve risk assessment in the general population and high-risk groups?
Does routine measurement of natriuretic peptides improve risk assessment in the general population and high-risk groups?
Answers are grounded in this paper and cite their sources.
Routine screening with natriuretic peptides for cardiovascular risk assessment is not currently recommended due to a lack of evidence for linked therapeutic interventions.
Recently there has been a growing interest in risk assessment of individuals, using biochemical markers of cardiac risk, with an increasing focus on a multi-marker strategy. Natriuretic peptides (BNP and NT-proBNP) are well-established markers of increased risk in the general population and in high-risk groups with hypertension, and coronary heart disease. However, there is at present no indication for routine measurements of natriuretic peptides in the risk assessment of individuals or patients, as there is no evidence for subsequent therapeutic initiatives. Natriuretic peptides are useful when screening for heart failure in symptomatic individuals. However, the use of NT-proBNP screening for risk or left ventricular systolic dysfunction in the general population is still a matter of debate.
No takes yet. Share an insight, caveat, or question.
Kragelund et al. (2005) conducted a review in Cardiac risk, hypertension, and coronary artery disease. Natriuretic peptides (BNP and NT-proBNP) was evaluated. Routine measurement of natriuretic peptides (BNP and NT-proBNP) for risk assessment in the general population or patients with hypertension and coronary disease is not currently indicated.
Synapse has enriched 10 related papers. Consider them for comparative context: